SCHEMBL6176922

SCHEMBL6176922

O=C(O)CC(Cc1ccc(O)cc1)c1ccco1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MIF P14174 1/20 0.80
PKM P14618 3/20 0.53
GAA P10253 1/20 0.53
HPGD P15428 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
KMT2A Q03164 7/20 0.48
MEN1 O00255 5/20 0.48
POLB P06746 4/20 0.48
MAPT P10636 3/20 0.48
NPSR1 Q6W5P4 3/20 0.48
CYP2C19 P33261 3/20 0.48
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
THRB P10828 1/20 0.48
CYP2C9 P11712 1/20 0.48
ALOX12 P18054 1/20 0.48
MAPK1 P28482 2/20 0.43
SLC7A5 Q01650 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6178054 0.83 MIF (0.72) MIFPKMGAAHPGDSMN1; SMN2
SCHEMBL27535219 0.83 MIF (0.56) MIFPKMGAAHPGDSMN1; SMN2
SCHEMBL6177276 0.78 GABBR2 (0.56) MIFMAPTKDM4ESLC7A5ESR2
SCHEMBL6178799 0.78 GABBR2 (0.56) MIFMAPTKDM4ESLC7A5ESR2
SCHEMBL6177284 0.78 GABBR2 (0.56) MIFMAPTKDM4ESLC7A5ESR2
SCHEMBL3931360 0.77 MIF (0.68) MIFPKMGAAHPGDSMN1; SMN2
SCHEMBL6179332 0.77 MIF (0.62) MIFPKMGAAHPGDSMN1; SMN2
SCHEMBL6178846 0.75 MIF (0.47) MIFSLC7A5ESR2CA2CAMK2A
SCHEMBL6177437 0.72 MIF (0.42) MIFPKMHPGDSMN1; SMN2KMT2A
SCHEMBL11220981 0.71 SLC7A5 (0.55) POLBSLC7A5ESR2CA2CAMK2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1061921-A4 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2005-03-30 EP disclosed
US-20020147334-A1 Vitronectin Receptor Antagonists SMITHKLINE BEECHAM CORPORATION 2002-10-10 US disclosed
EP-1061921-A1 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2000-12-27 EP disclosed
WO-1999045927-A1 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1999-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147334-A1 Vitronectin Receptor Antagonists ADGRF1, FN1, CALCR MIF 1330/4885PKM 4524/4885GAA 3356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.